Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Liver source : Www.biospace.com save search
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
OABI | News | $4.56 -1.72% -1.75% 560K
|
|
| O: -1.58%
H: 1.77%
C: -0.4%
drug liver disease antibody for
Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
CANF | $1.94 -1.52% 0.0% 5.7K
|
Health Technology
|
| O: 4.76%
H: 0.45%
C: -5.91%
drug candidate liver cancer treat namodenoson advanced
Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference
Published: 2024-03-11 (Crawled : 12:30) - biospace.com/
CANF | $1.94 -1.52% 0.0% 5.7K
|
Health Technology
|
| O: -0.45%
H: 2.27%
C: 2.27%
europe liver conference distribution pancreatic treatment namodenoson
MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024MiNK-215 Eradicated Tumor Cells in Human Organoid MSS Colorectal Cancer Liver Metastases Model
Published: 2024-03-06 (Crawled : 14:00) - biospace.com/
INKT | $0.872 0.12% 0.11% 38K
|
|
| O: 1.02%
H: 0.48%
C: -1.41%
nk-215 liver cancer tumor preclinical
Better Therapeutics Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease
Published: 2024-02-20 (Crawled : 15:30) - biospace.com/
BTTX | $0.006 -65.02% 340K
|
|
| O: 7.55%
H: 2.13%
C: -27.83%
fda device liver disease designation therapeutics advanced platform
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
Published: 2024-02-12 (Crawled : 14:30) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: -0.35%
H: 2.36%
C: 1.42%
CBAY | $32.48 0.03% 8.4M
|
Health Technology
|
| O: 27.92%
H: 0.97%
C: 0.88%
liver acquisition sciences therapeutics
Better Therapeutics Announces Submission for FDA Breakthrough Device Designation for Digital Therapeutic Platform to Treat Liver Disease
Published: 2024-01-02 (Crawled : 13:00) - biospace.com/
BTTX | $0.006 -65.02% 340K
|
|
| O: 4.1%
H: 0.3%
C: -10.0%
fda device liver disease treat designation therapeutics platform submission
CymaBay Announces an Oral Presentation of Seladelpar Phase 3 Pivotal Results in Primary Biliary Cholangitis at the Late Breaker Session of the Liver Meeting®
Published: 2023-11-13 (Crawled : 14:30) - biospace.com/
CBAY | $32.48 0.03% 8.4M
|
Health Technology
|
| O: 7.07%
H: 6.73%
C: 6.03%
meeting liver presentation results
Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD’s The Liver Meeting® 2023
Published: 2023-11-13 (Crawled : 14:30) - biospace.com/
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: 1.02%
H: 4.5%
C: 3.38%
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: 0.04%
H: 1.92%
C: 1.89%
meeting hepatitis liver ongoing trials today
Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD’s The Liver Meeting® 2023
Published: 2023-11-10 (Crawled : 15:00) - biospace.com/
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: 0.98%
H: 7.06%
C: 6.93%
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: 0.49%
H: 0.74%
C: -2.08%
meeting hepatitis liver ongoing trials
Precision BioSciences Announces Late-Breaking Poster Presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting
Published: 2023-11-09 (Crawled : 13:00) - biospace.com/
DTIL | $9.81 -4.11% -4.28% 34K
|
Health Technology
|
| O: 3.03%
H: 1.23%
C: -2.72%
liver association presentation meeting study
Aligos Therapeutics to Present Multiple Posters at AASLD’s The Liver Meeting® 2023, Highlighting Progress for Its Clinical Stage Portfolio
Published: 2023-11-07 (Crawled : 16:00) - biospace.com/
ALGS | $0.8204 -0.39% -0.39% 640K
|
Health Technology
|
| O: 5.13%
H: 0.13%
C: -7.88%
meeting liver therapeutics
ENDRA to Host Multidisciplinary Clinical Discussion on Managing Liver Disease During AASLD’s The Liver Meeting® 2023
Published: 2023-11-06 (Crawled : 14:00) - biospace.com/
NDRA | $0.2546 0.08% 0.08% 42K
|
Health Technology
|
| O: 3.13%
H: 4.03%
C: -5.05%
meeting liver disease
Gilead to Present Late Breaking Data and Real World Evidence Highlighting Key Hepatitis Indications at The Liver Meeting® 2023
Published: 2023-11-03 (Crawled : 17:00) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.95%
H: 0.72%
C: -0.5%
meeting hepatitis liver world
Mirum Pharmaceuticals to Present New Data at The Liver Meeting®
Published: 2023-10-30 (Crawled : 13:00) - biospace.com/
MIRM | $24.0 -1.72% -1.75% 320K
|
Health Technology
|
| O: 0.85%
H: 1.21%
C: -0.44%
meeting liver pharmaceuticals
Salix Pharmaceuticals Releases Liver Health Annual Trends Report Identifying Increase in Chronic Liver Disease and Cirrhosis-Related Deaths Marking These as Ninth Leading Cause of Death in U.S.
Published: 2023-10-10 (Crawled : 13:30) - biospace.com/
BHC | $8.56 0.35% 0.0% 2M
|
Health Technology
|
| O: 1.18%
H: 1.81%
C: 0.52%
liver disease report health pharmaceuticals trends
Better Therapeutics Announces Publication of LivVita Liver Disease Study Results in Gastro Hep Advances
Published: 2023-10-05 (Crawled : 12:00) - biospace.com/
BTTX | $0.006 -65.02% 340K
|
|
| O: 1.13%
H: 5.96%
C: -7.68%
liver disease publication therapeutics results study
Abstract for ENDRA Life Sciences' TAEUS System Accepted for Presentation at EASL Steatotic Liver Disease Summit 2023
Published: 2023-09-07 (Crawled : 18:00) - biospace.com/
NDRA | $0.2546 0.08% 0.08% 42K
|
Health Technology
|
| O: 0.0%
H: 4.59%
C: 3.68%
liver disease taeus life presentation system
Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics
Published: 2023-09-05 (Crawled : 14:00) - biospace.com/
TVTX | $5.46 -4.88% -5.13% 2M
|
Health Technology
|
| O: -1.08%
H: 2.24%
C: -3.54%
MIRM | $24.0 -1.72% -1.75% 320K
|
Health Technology
|
| O: 0.42%
H: 7.76%
C: 4.46%
rare liver treatment acquisition pharmaceuticals therapeutics
Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics
Published: 2023-07-17 (Crawled : 13:20) - biospace.com/
TVTX | $5.46 -4.88% -5.13% 2M
|
Health Technology
|
| O: 5.16%
H: 0.75%
C: -1.43%
MS | News 0 d | $93.85 0.1% 0.0% 4.8M
|
Finance
|
| O: -0.12%
H: 1.42%
C: 0.81%
MIRM | $24.0 -1.72% -1.75% 320K
|
Health Technology
|
| O: 1.18%
H: 7.3%
C: 2.18%
rare liver treatment pharmaceuticals acquire therapeutics agreement
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.